Actively Recruiting
Safety and Efficacy of Balloon Pulmonary Angioplasty in China
Led by Chinese Pulmonary Vascular Disease Research Group · Updated on 2023-12-20
200
Participants Needed
2
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Balloon pulmonary angioplasty (BPA) is a potential treatment for non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study was to evaluate the safety and efficacy of BPA in CTEPH patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA.
CONDITIONS
Official Title
Safety and Efficacy of Balloon Pulmonary Angioplasty in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) according to ESC Guidelines, including mean pulmonary artery pressure ≥ 25 mmHg at rest or exercise limitations from chronic thromboembolic disease with abnormal imaging confirming disease
- Treated with anticoagulation for at least 3 months before CTEPH diagnosis
- Not suitable for pulmonary endarterectomy surgery
- Willing to provide informed consent
You will not qualify if you...
- Unwilling or unable to provide written consent for study participation
- Unable to complete follow-up visits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
center of pulmonary vascular disease, Fuwai hospital
Beijing, China, 100037
Actively Recruiting
2
Chinese Academy of Medical Sciences Fuwai hospital
Beijing, China, 100037
Actively Recruiting
Research Team
Z
Zhihong Liu, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here